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Abstract
Purpose. The purpose is to review the natural history, the clinicopathological prognostic factors, and the role of adjuvant
radiation therapy with particular attention to the limited but favorable experience with IORT.
Methods. Retroperitoneal sarcomas present a continuing therapeutic challenge to the oncologist.In contrast to sarcomas of
the extremity and super® cial trunk in which complete resection plus radiation therapy results in excellent local control,
sarcomas of the retroperitoneum are difficult to resect and even if completely resected, demonstrate high rates of local
relapse, the primary pattern of failure. Due to the proximity of normal organs, the delivery of therapeutic doses of adjuvant
external beam radiation therapy is problematic.To deliver adequate doses (>60 Gy) of external beam to most patients would
result in unacceptable toxicity. The therapeutic dilemma is unfortunate and better strategies are needed. One attractive
approach has been to incorporate intraoperative radiation therapy (IORT) with maximal resection and external beam radia-
tion.
Results and Discussion. A number of institutions have explored this approach with encouraging preliminary results.
Key words: retroperitoneal sarcoma, intraoperative radiation therapy (IORT), high-dose rate IORT, electron beam, complications
Introduction
Retroperitoneal sarcomas present a continuing chal-
lenge to the oncologist. With only 1000 cases
diagnosedper year in the USA,they are a rare tumor,
comprising about 15% of all sarcomas and 40% of all
primaryretroperitonealtumors.
1Theirrarity impedes
data collection and limits the power of adequately
designed trials. In contrast, the published data with
extremity sarcoma is more extensive. It has been
clearly documented that complete resection plus
radiation therapy can locallycontrolthe overwhelming
majority of extremity sarcomas and super® cial
trunk.
2± 19 In this regard, the radiation therapy
approach can be either by external beam, brachy-
therapy or a combination of both, yielding local
control rates of 80± 90% and 5-year overall survival
of 80%.
7,8,16,20Sarcomasof the retroperitoneumhave
been a far different story. Due to its remote location
with multipleadjacentcritical organs,sarcomasarising
from this location present as large, advanced stage
tumors that are difficult to resect with adequate
margin. The proximity of normal organs such as
viscera and neurovascular structures has made the
delivery of therapeutic doses of postoperative external
beam irradiation problematic. To deliver adequate
doses (>60 Gy) of external beam radiation would
result in unacceptable toxicity. The therapeutic
dilemma is unfortunate and better strategies are
needed. One attractive approach has been to
incorporate intraoperative radiation therapy using
either electrons (IOERT) or high-dose rate photons
delivered via remote afterloading (HDR-IORT) with
maximal resection and external beam radiation.The
purpose of this review is to overview the need for
effective adjuvant radiation after maximal resection
of retroperitoneal sarcomas and to report the limited
but encouragingexperience using IORT in combina-
tion with conventional external beam radiation.
Clinicopathological prognostic factors
Achieving a gross total resection (GTR) of either a
primary or recurrent retroperitoneal sarcoma is by
far the most important predictive factor for local
control and survival.
1,21± 24 When GTR is achieved,
5-year overall survival is about 50% (range 35± 74%,
Table 1) Moreover, after GTR, the microscopic
residual disease status appears important as patient
with microscopicdiseasepresentappear to have worse
survival
25 and/or local control
22 compared to those
with negative residual.The outlook for patients with
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less than 5%.
21,26 Given the importance of achieving
GTR, aggressive surgery must be pursued.To obtain
a maximal en bloc resection, it is common to resect
abutting organs.
21,27IntheMemorialSloan-Kettering
Cancer Center (MSKCC) series, Jacques
demonstrated that that resection of adjacent organs,
primarily kidney, bowel or pancreas was required in
83% of cases.
21 Despite such aggressive approaches,
the rate of gross total resection is about 40± 50% of
all patients who presentfor resection.
1,21,28,29Of 500
patients who presented at MSKCC, only 64% of
primary tumors and 52% of recurrentsarcomas were
grossly resected.
30 Among patients presenting with
primary tumors that were resected with grossly nega-
tive margins,median overall survival was 103 months
vs 18 months for those with primary tumors in which
gross residual disease remained. There was no
signi® cant differencein survival between patients who
were unresectable and those who underwent
incomplete resection.
Aside from the extent of resection, the prognostic
value of other clinicopathological factors are
controversial. Most studies analyzing prognostic
factors have evaluated the impact primarily of grade,
histology, tumor stage and presentation status.
1,21,25±
27,30± 33 In the majority of these studies, high-grade
lesions appear to confer a worse survival by as much
as 30± 70% compared with low-grade
lesions;
21,26,27,31± 33 however, studies from several
major centers have not demonstrated any impact of
grade on survival.
22± 24,28 Among the studies that
evaluate whether grade impacts on patterns of
failure,
28,30,34± 36four suggestthat high-grade tumors
are associated with an increased incidence of distant
metastases with three of them showing no impact on
local failure while one found that high-grade designa-
tion increased the risk for local failure. On the other
hand,two studiessuggestthat high-gradetumorstatus
has no in¯ uence on the rates of distant metas-
tases.
1,22 Lewis reported recently an analysis of
prognostic factors based on data of 231 MSKCC
patients with primary disease undergoing GTR.
30
High-grade status was associated with worse disease-
speci® c mortality [relative risk (RR)=3.2, p=0.001],
higher risk for distant metastases (RR=5, p=0.01)
and increasedlocal failure (RR=2,p=0.01).However,
follow-up is short with a median time of 2.3 years.
With median follow-up of 6.3 years, the data from
PrincessMargaret Hospital (PMH) demonstratedno
survival impact of grade.
23The experiencefromMayo
suggested that the apparent in¯ uence of grade on
survival in an earlierreportwas lost with longerfollow-
up.
22
Similarcon¯ ictingdata existfor histologicalsubtype
and presentation, but not tumor stage. Five studies
suggest that histological subtype has no impact on
survival but four of these report that it affects the rate
of distant metastases.
21,26,30,31,34 Two of these
suggested that leiomyosarcoma is associated with a
decrease rate of distant metastases,
30,34 but one
reportsthe opposite effectof leiomyosarcoma.
21Lewis
reported that liposarcoma had a higher rate of local
recurrence (RR=2.6, p=0.01) but did not impact on
disease-speci® c survival most likely due to its nega-
tive association with metastasis (RR=0.2,p=0.01). In
contrast, two studies report that histological subtype
can impact on survival, both associating liposarcoma
with improved survival.
23,37 Recurrent presentation
status had no statistically signi® cant impacton survival
in one study
22 but did in another.
30 Tumor size is
reported consistently not to in¯ uence
survival
21,31,33,34or riskfor local failure.
31,33However,
T3 lesions(based on the Russellstagingsystem)which
invade adjacent organs have been reported to impact
negatively on survival.
31,33Of 198 patients who were
followed for at least 5 years, Heslin reported that
patients alive at 5 years tendedto presentwith primary
low-grade, liposarcomas in which GTR was
achieved.
34
Patterns of failure after gross total resection
After GTR, patterns of failure studies indicate that
local relapse represents the primary mode of failure.
However,local failure after complete resection occurs
Table 1. Local control and survival after gross total resection of retroperitoneal sarcomas
Tx Date
No. of
patients
Med F/U
(years) %HG
%RT
(median
dose)
5-year LR
(actuarials %)
5-year OS
(actuarials) %
MSKCC
30 1982± 97 185* 2.3 58 NS 41 70
MSKCC
21 1982± 87 67 2.6 55 NS 49 74
U Fla
27 1970± 94 49 NS 54 NS 46 (crude) 58
MSKCC
32 1951± 77 47 NS NS 40 (NS) 77 40
PMH
23 1975± 88 45 6.3 NS 80 (40 Gy) 50 (10 year 82%) 55 (10 year 22%)
Univ. Minn.
37 1941± 87 31 11 77 NS NS 48
Netherlands
24 1973± 90 29 3.2 44 45 63 35
Roswell Park
6 1957± 80 27 NS NS NS NS 64
MCV
26 1964± 82 18 NS NS 33 (NS) 56 (crude) 70
HG=high grade, LR=local recurrence, OS=overall survival, NS=not stated, MSKCC=Memorial Sloan-Kettering Cancer
Center, PMH=Princess Margaret Hospital, MCV=Medical College of Virginia, *All patients presented with primary
tumors.
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MSKCC, local failure alone as a ® rst site of recur-
rence occurred in 81% of all failures and was a
component of 90% of failures.
21 Distant metastases
to lung or liver accounted for 19% of all ® rst failures.
Local failure alone comprised a higher proportion of
® rstfailuresfor those presentingwith recurrentdisease
compared to those presenting with primary disease
(92% vs. 67%, respectively). In a literature review of
310 patients achieving gross total resection, Fein
showed that 47% recurred locally while 21%
developed distant metastases.
28 Of 135 recurrent
cases, 81% had a local component of failure and
37% had a distant component. Common life-
threatening complications resulting from local recur-
rence include sepsis, gastrointestinal bleeding,
obstruction, perforation, ® stula, biliary obstruction
and obstructive nephropathy.
32 Due to the high local
failure rates despite maximalsurgery,the role of adju-
vant treatment becomes crucial.
Adjuvant external beam radiation
Based on the highlysuccessfulexperiencein extremity
sarcoma, it is clear that radiation delivered either by
external beam radiotherapy (EBRT) or brachy-
therapy (BT) can serve as effective adjuvant treat-
ment for sarcoma.
7,8,10,16,20 To control grossly
resected extremity sarcomas, EBRT doses of 60± 70
Gy or BT doses of 45 Gy are needed.
7,8,16,20
Combined BT (15± 20 Gy) plus EBRT (45± 50 Gy)
have also been used.
10 Achieving such doses to treat
retroperitoneal sarcomas is problematic due to the
radiation tolerance of the surroundingorgans as well
as the large areas that need to be addressed.Tepper’s
study suggested that a post-operative EBRT dose
greater than >60 Gy produced better local control
83% (5/6) vs 33% (2/6) for <50 Gy.
38Catton showed
that the addition of radiation increased the time to
in-® eld local failure from 30 to 103 months (p<0.05),
especially if a dose of >35 Gy was delivered.
23 Fein
showed that of 21 retroperitoneal sarcoma patients,
local failure was 25% (2/8) vs 38% (5/13) if the dose
delivered was <55.2 Gy vs >55.2 Gy.
28 Cody
demonstratedan increasein 5-year survival rates from
30 to 53% in 15 patients who receivedadjuvant radia-
tion after GTR compared to 22 who had GTR alone;
however, this was not statistically signi® cant and a
detailed comparison of the treatment groups was not
performed.
32 Heslin showed that among 5-year
survivors, radiation therapy was the only signi® cant
factor on univariate analysis that decreasedlocal recur-
rence.
34
Delivering doses greater than 50± 55 Gy with
standard EBRT technique is toxic. In the NCI trial,
54± 55 Gy produceda 50% chronic enteritis and 25%
® stula rate.
29Glenn reported a severe enteritis rate of
22% (8/37) in patients receivinga dose of 54 Gy after
GTR, of whom seven required surgery and one died
frombowel perforation.
33Tissueexpandersto displace
bowel as well as various radiation therapy treatment
techniques (decubitis position, oblique ® elds) may
improve tolerance to modest doses (50± 55 Gy) but
do not in generalpermit therapeutic doses.Preopera-
tive radiation has been advocated to improve resecta-
bility and minimizebowel toxicity;however,itsefficacy
remains to be demonstrated and achieving doses for
optimal control is not feasible.
22,39
Clinical experience with IORT in the treatment
of retroperitoneal sarcoma
The addition of IORT to maximal resection and
EBRT representsan attractive approach to delivering
more effective adjuvant treatment.To date, there has
been only a limited experience with this approach
(Table 2). A randomized trial at the NCI showed
signi® cantly better local control with IOERT and
post-operative EBRT 40% (6/15) vs post-operative
EBRT alone 80% (16/20) p<0.05 at a median
follow-up of 8 years.
29 All patients underwent gross
total resection and were randomized to either EBRT
of 35± 40 Gy and 20 Gy IORT with misonidazole or
to 50± 55 Gy of EBRT alone. The IOERT arm
experiencedsigni® cantly more peripheralneuropathy
(60% vs 5%, p<0.05), while the EBRT only arm had
a signi® cantly higherrate of gastrointestinalcomplica-
tions, including a higher rate of disabling chronic
enteritis [50% (10/20) vs 7%(2/15),respectively] and
® stula [25% (5/20) vs 0%(0/15), respectively]. The
higher incidence of peripheral neuropathy in the
IORTarm was attributed to multiplefactors including
the doseof 20 Gy, the use of a concomitant radiosen-
sitizer which itself is neurotoxic, and the use of large
pelvic electron ® elds near the lumbosacral plexus.
The MGH experience with IOERT was also favo-
rable (Table 2).
39 Of 20 patients receiving preopera-
tive EBRT to 40± 50 Gy,14 had a complete resection.
Ten of the 14 completely resected patients received
IORT to a median dose of 15 Gy (10± 15 Gy) for
microscopic residual tumor, while the other four
received no further because of extensive tumor beds
that could not be encompassed in an IORT ® eld. At
a median follow-up of 3 years, only 10% (1/10) who
underwent GTR and IORT failed locally. Seven of
10 are NED, while three developed metastasis. None
of the 10 patients undergoing IORT and GTR
developed neuropathy. One of two patients who
received IORT and EBRT for gross residual disease
developed a sensory neuropathy after receiving 17.5
Gy of IORT. Bowel toxicity was minimal with only a
6% small bowel obstruction rate.At the same institu-
tion in a cohort of patients treated with resection and
postoperative EBRT without IORT, the 5-year local
control and survival rates were both 54%.Thus, the
addition of IORT appeared to improve local control
and possibly survival.
Other important limited experiences with IOERT
have been reported (Table 2).The Radiation Therapy
OncologyGroup(RTOG) conducteda phase II study
Radiation therapy of retroperitoneal sarcoma 13of intraoperative radiation for retroperitoneal
sarcomas.
40 A preliminary analysis of 12 patients
treated with EBRT (45± 50.4 Gy) plus IOERT
(12.5± 20 Gy) demonstrated a local failure of 17% at
a median follow-up of 18 months. At the Institut
Bergonie, 19 retroperitoneal sarcomas were treated
with IOERT after maximal resection. GTR was
achieved in 79% (15/19).
41The median IOERT dose
was 17 Gy (15± 20 Gy) with 13/19 receiving EBRT at
a median dose of 50 Gy (30± 60 Gy). At a median
follow-up of 17 months,2-year actuarial local failure
was 24% with 2-year overall survival of 60%. Severe
late complications occurredin 6/19 patients and were
likely multifactorial in origin with one `moderate’
peripheral neuropathy and one iliac vessel rupture.
Petersen at the Mayo Clinic reported the largest
experience with IOERT in the treatment of 87 retro-
peritoneal sarcoma who had received maximal resec-
tion and preoperative EBRT.
22 Eighty-three per cent
(72/87) were able to undergo GTR with 64% having
microscopicresidualand 20% had no residualtumors.
All primary tumors (43/87) and 77% of recurrent
tumorsreceived a preoperative EBRT doseof 45± 48.6
Gy.All patients receivedintraoperative electron radia-
tion to a median doseof 15 Gy.Ata median follow-up
of 3.5 years, 23% (20/87) developed a local recur-
rence with a 3- and 5-year actuarial local recurrence
of 23 and 41%, respectively.The amount of residual
disease signi® cantly affected local control with 5-year
local failure of 0% for no residual, 43% for
microscopic residual and 63% for gross residual
tumors(p=0.04). Interestingly,local relapse occurred
in only 7% (3/43) of primary tumors treated with
IORT, EBRT and GTR. Five-year overall survival
after grosstotal resectionwas 49%.Grade3 peripheral
neuropathy occurred in 10% (9/87) while grade 3
gastrointestinal toxicities occurred in 14% (12/87)
consisting mainly of ® stula and proctitis. No grade 4
toxicities were reported.
The preliminaryMemorialSloan-KetteringCancer
Center experience using HDR-IORT has been
reported and is also favorable.
35,36 In a prospective
protocol, 32 patients were treated with gross total
resection and HDR-IORT (12± 15 Gy) followed by
post-operative EBRT (45± 50.4 Gy).HDR-IORTwas
delivered using a cable-mounted iridium-192 source
into a super¯ ab afterloading applicator. Twelve
patients presented with primary and 20 with locally
recurrent disease.Two-thirds of the patient (20/32)
had high-grade disease and the median tumor size
was 203 12.53 11 cm. At a median follow-up of 33
months (range 1± 77 months), the 4-year actuarial
local failure for all patients was 38%. Subset analysis
demonstrated that local failure for primary tumors
was 26% vs 46% in recurrentdisease (p=0.4). Tumor
grade did not impact on the rate of local failure (40%
vs 33% for high- and low-grade tumors, respectively,
p=0.66). A statistically signi® cant higher 4-year
actuarial rate of distant metastases was detected in
the high-grade vs low-grade tumors (30% vs 0%,
p=0.05, respectively). Four-year actuarial disease-
free and overall survival were 55 and 45%,
respectively. Neither presentation status nor tumor
grade impacted on disease-free or overall survival. In
this challenging group of patients treated with an
aggressive combined modality regimen, 34%
developed complications, the majority of which were
multifactorial in etiology and resolved with conserva-
tive management. Bowel obstruction was the most
common complication (18%) and ® stula formation
occurred in 9%. Also noteworthy was a 6% (2/32)
Table 2. Efficacy of IORT in the treatment of retroperitoneal sarcoma
TX Date
No. of
patients
Med
F/U
(years) %GTR %HG RT Dose
5 year LR
(actuarial, %)
5 year OS
(actuarial, %)
Mayo Clinic
22 1981± 97 88 3.5 81 62 48.6 Gy EBRT+ 41 47
15 Gy IORT
NCl
29 NS 20 100 NS 54± 55 Gy EBRT 80 25
8 vs [8-year] [8-year]
15 p=0.05
15 35± 40 Gy EBRT+ 40 20
20 Gy IORT [8-year] [8-year]
MSKCC
35 1992± 96 32 2.8 84 62 45 Gy EBRT+ 38 56
15 Gy IORT [4-year] [4-year DFS]
Institut Bergonie
41 1991± 94 19 1.4 74 74 50 Gy EBRT+ 24 60
(Grade
2,3)
17 Gy IORT [2-year] [2-year DFS]
MGH
39 1981± 89 17 3 82 76 40± 50 Gy EBRT+ 19 64
15± 20 Gy IORT [59%] [4 year] [4-year DFS]
RTOG
40 NS 12 1.5 NS 40± 50 Gy EBRT+ 17
12.5± 20 Gy IORT [2 year]
GTR=gross total resection, HG=high grade, LR=local recurrence, OS=overall survival, DFS=disease free survival,
NCI=National Cancer Institute, MGH=Massachusetts General Hospital, NS=not stated, MSKCC=Memorial Sloan-
Kettering Cancer Center, RTOG=RadiationTherapy Oncology Group.
14 K.S. Hu & L.B. Harrisonincidence of femoral nerve palsy which were mild
and healed without major intervention.
The low rate of peripheral neuropathy is reas-
suring. Based on animal studies and the NCI rand-
omized trial, the main toxicity associated with IORT
is peripheral neuropathy.
42 A dose of 20 Gy appears
to be toxic as signi® cantratesof peripheralneuropathy
developed in the NCI trial (60%), while doses of 15
Gy or less appeared to be better tolerated (36%).
One of the potential problems with IOERT is the
dependenceon unwieldy,rigid electron cones to treat
narrow, anatomically complex surfaces. In addition,
if the target is large, abutting electron ® elds must be
used.These factors introduce dosimetric inhomoge-
neities that may underdose the target or overdose
adjacent normal tissue. In the NCI trial, the most
common situation associated with the development
of clinically debilitating peripheral neuropathy was
the use of angled, abutting electron ® elds to treat
large pelvic tumors. Although the signi® cantly lower
rate of peripheral neuropathy noted in the MSKCC
series may be due to a different patient population or
differences in shielding techniques, it possibly is
related to the type of applicator used. In contrast to
the electron cone, the Harrison± Anderson± Mick
(HAM) applicator used in the MSKCC study is ¯ ex-
ible enough to conform to most tumor beds and can
be abutted without junctional dosimetric inhomoge-
neity. A low rate of peripheral neuropathy was also
reported in rectal cancer patients treated with
HDR-IORT using the HAM applicator in a separate
MSKCC study.
43± 45
Conclusion
In summary, the preponderance of the data support
the hypothesis that IORT can improve local control.
When compared to the local recurrence rates of
41± 82% after gross total resection without IORT
(Table 1), the ® ve studies evaluating this modality,
includinga randomizedtrial,indicatethat IORT does
appear to decrease local failure to rates of 19± 41%
(Table 2). However, with the exception of the 8-year
follow-up of the randomized NCI trial, follow-up of
most of the other studies is modest.The importance
of long-termobservationwas demonstratedby Heslin,
who showed that local failure can commonly occur
even in 5-year survivors at up to 5% per year.
34Thus,
close surveillance is required to con® rm the bene® t
of IORTon local control.Nevertheless,IORTappears
to improvelocal controlin other sites includingcolor-
ectal, pancreatic and gastric cancers.
46
Theoretically, since local recurrencerepresentsthe
primary mode of failure and underlies the cause of
death in the majority of retroperitoneal sarcoma
patients, it would seem that a survival bene® t should
be derived from the incorporation of IORT. Yet an
obvious improvement in survival is not apparent. It
may be that too few patients treated with IORT have
been studied as data of only 183 patients have been
reported or it is possible that follow-up is too short to
make a ® rm conclusion. The improvement in local
control without a survival bene® t has been
demonstrated for extremity sarcomas.
20 Moreover,
given the morbidity and mortality associated with
local failure,local control remainsa worthy objective.
IORT seems to be a promising new modality for the
50% of patients whose retroperitoneal sarcomas may
be gross totally resected; however, its role in subto-
tally resected patients remains to be de® ned. New
treatment approaches integrating IORT, possibly
concurrently with new chemotherapeutic or other
biological agents need to be investigated.
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